Mark Talamonti to Biomarkers, Tumor
This is a "connection" page, showing publications Mark Talamonti has written about Biomarkers, Tumor.
Connection Strength
0.518
-
NuMA: evaluation of a new biomarker for the detection of low stage colorectal cancer. Anticancer Res. 1999 Jul-Aug; 19(4A):2411-4.
Score: 0.098
-
CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Am J Clin Oncol. 2014 Dec; 37(6):550-4.
Score: 0.071
-
Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2014 Dec; 156(6):1504-10; discussion 1510-1.
Score: 0.071
-
Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012 Oct; 61(10):1454-64.
Score: 0.058
-
Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 2009 Feb 01; 99(2):119-22.
Score: 0.048
-
Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol. 2008 Sep; 21(9):1075-83.
Score: 0.046
-
5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005 Jul 15; 65(14):6011-6.
Score: 0.037
-
Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein. Biochem Biophys Res Commun. 2005 Apr 08; 329(2):755-64.
Score: 0.037
-
Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep. 2001 May-Jun; 8(3):497-500.
Score: 0.028
-
Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer. 2010 Apr 01; 116(7):1674-80.
Score: 0.013
-
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20; 26(6):942-7.
Score: 0.011